Tag: Health Care

Displaying 661 - 680 of 853 results.

Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and...
Under the terms of a proposed consent agreement announced today, the Federal Trade Commission would allow Amgen Inc.'s (Amgen) proposed $16 billion acquisition of Immunex Corporation (Immunex) to proceed, provided the companies divest certain assets and license certain intellectual property rights...
In an initial decision filed on June 27, 2002 and announced today, Administrative Law Judge (ALJ) D. Michael Chappell dismissed all allegations of anticompetitive conduct in a March 2001 Federal Trade Commission complaint against pharmaceutical manufacturers Schering-Plough Corporation (Schering)...
Two Denver, Colorado-area physician organizations, Physician Integrated Services of Denver, Inc. (PISD), and Aurora Associated Primary Care Physicians, L.L.C. (AAPCP), along with their respective physician leaders and non-physician agent, have agreed to settle Federal Trade Commission charges that...
A consent order settled charges that a Denver, Colorado physician organization and its members, its president, Dr. M. J. Guese, and its non-physician consultant, M. A. Brauchler, increased fees for services through collective boycotts and agreements in a effort to fix the prices they...
A consent order settled charges that the organization of internists, pediatricians, family physicians and general practitioners in the Aurora, Colorado area engaged in boycotts and entered into collective negotiations with health care insurers in an effort to increase the costs of...
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed...
The Federal Trade Commission today announced its first complaint against - and consent order with - a pharmaceutical manufacturer for allegedly illegally acquiring an exclusive patent license and wrongfully listing that patent in the U.S. Food and Drug Administration's (FDA) "Orange Book" for the...
A doctors’ group consisting of nearly every obstetrician and gynecologist with active medical staff privileges at the two general acute care hospitals in Napa County, California settled charges that they restrained price and other competition by engaging in illegal agreements to fix...
The staff of the Federal Trade Commission recently told the Alaska House of Representatives' Committee on Labor and Commerce that legislation authorizing collective bargaining among the state's physicians would significantly increase health care costs in the state and harm its consumers....
The Federal Trade Commission today announced a consent agreement with American Home Products Corporation (AHP) that would settle charges that the company entered into an anticompetitive agreement with Schering-Plough Corporation (Schering) to delay entry of a lower-cost generic drug into the U.S....
A bill introduced in the Washington state legislature that seeks to authorize competing physicians, and other providers, to engage in collective bargaining with health plans over a variety of contract terms and conditions, including fees, would significantly increase health care costs and harm...
A bill pending before the Alaska legislature that seeks to authorize competing physicians to engage in collective bargaining with health plans over fees and other terms would significantly increase health care costs and harm consumers, according to the staff of the Federal Trade Commission. The...
The FTC has approved the issuance of two briefs, both of which are available on the Commission's Web site. The briefs were filed with respect to litigation involving: 1) Bristol-Myers-Squibb and Buspirone; and 2) The Hearst Trust and First Data Bank. A basic description of each brief is provided...
Amicus brief for the Federal Trade Commission, supporting argument of generic drug manufacturer that allegedly wrongful listing of patents in the FDA's "Orange Book" is not immune from antitrust liability.

Pages